407 related articles for article (PubMed ID: 24144415)
1. Indazoles: a new top seed structure in the search of efficient drugs against Trypanosoma cruzi.
Aguilera-Venegas B; Olea-Azar C; Arán VJ; Speisky H
Future Med Chem; 2013 Oct; 5(15):1843-59. PubMed ID: 24144415
[TBL] [Abstract][Full Text] [Related]
2. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
3. New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and mechanism of action studies.
Rodríguez J; Arán VJ; Boiani L; Olea-Azar C; Lavaggi ML; González M; Cerecetto H; Maya JD; Carrasco-Pozo C; Cosoy HS
Bioorg Med Chem; 2009 Dec; 17(24):8186-96. PubMed ID: 19900812
[TBL] [Abstract][Full Text] [Related]
4. Trypanocidal activity of 4 isopropyl salicylaldehyde and 4-isopropyl salicylic acid on Trypanosoma cruzi.
Nogueda-Torres B; Rodríguez-Paez L; Ramírez IB; Ramírez CW
Rev Latinoam Microbiol; 2001; 43(1):1-6. PubMed ID: 17061565
[TBL] [Abstract][Full Text] [Related]
5. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.
Beltran-Hortelano I; Perez-Silanes S; Galiano S
Curr Med Chem; 2017 May; 24(11):1066-1138. PubMed ID: 28025938
[TBL] [Abstract][Full Text] [Related]
6. Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase.
Arias DG; Herrera FE; Garay AS; Rodrigues D; Forastieri PS; Luna LE; Bürgi MD; Prieto C; Iglesias AA; Cravero RM; Guerrero SA
Eur J Med Chem; 2017 Jan; 125():1088-1097. PubMed ID: 27810595
[TBL] [Abstract][Full Text] [Related]
7. [The chemotherapy of Chagas disease].
Stoppani AO
Medicina (B Aires); 1999; 59 Suppl 2():147-65. PubMed ID: 10668258
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of Chagas' disease].
Apt W
Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
[No Abstract] [Full Text] [Related]
9. Developments on treatment of Chagas disease - from discovery to current times.
Custodio Leite TO
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2576-2586. PubMed ID: 30964186
[TBL] [Abstract][Full Text] [Related]
10. The chemotherapy of chagas' disease: an overview.
Paulino M; Iribarne F; Dubin M; Aguilera-Morales S; Tapia O; Stoppani AO
Mini Rev Med Chem; 2005 May; 5(5):499-519. PubMed ID: 15892691
[TBL] [Abstract][Full Text] [Related]
11. Challenges in Chagas Disease Drug Discovery: A Review.
Paucar R; Moreno-Viguri E; Pérez-Silanes S
Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy of Chagas' disease: status and new developments.
Cerecetto H; González M
Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
[TBL] [Abstract][Full Text] [Related]
13. Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi.
Belluti F; Uliassi E; Veronesi G; Bergamini C; Kaiser M; Brun R; Viola A; Fato R; Michels PA; Krauth-Siegel RL; Cavalli A; Bolognesi ML
ChemMedChem; 2014 Feb; 9(2):371-82. PubMed ID: 24403089
[TBL] [Abstract][Full Text] [Related]
14. Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved?
Boiani M; Piacenza L; Hernández P; Boiani L; Cerecetto H; González M; Denicola A
Biochem Pharmacol; 2010 Jun; 79(12):1736-45. PubMed ID: 20178775
[TBL] [Abstract][Full Text] [Related]
15. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
[TBL] [Abstract][Full Text] [Related]
16. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
17. Enantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma cruzi activity, toxicity, or pharmacokinetic properties.
Moraes CB; White KL; Braillard S; Perez C; Goo J; Gaspar L; Shackleford DM; Cordeiro-da-Silva A; Thompson RC; Freitas-Junior L; Charman SA; Chatelain E
Antimicrob Agents Chemother; 2015; 59(6):3645-7. PubMed ID: 25845874
[TBL] [Abstract][Full Text] [Related]
18. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.
Leite DI; Fontes FV; Bastos MM; Hoelz LVB; Bianco MDCAD; de Oliveira AP; da Silva PB; da Silva CF; Batista DDGJ; da Gama ANS; Peres RB; Villar JDF; Soeiro MNC; Boechat N
Chem Biol Drug Des; 2018 Sep; 92(3):1670-1682. PubMed ID: 29745048
[TBL] [Abstract][Full Text] [Related]
19. The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.
Molina I; Perin L; Aviles AS; de Abreu Vieira PM; da Silva Fonseca K; Cunha LM; Carneiro CM
Acta Trop; 2020 Jan; 201():105218. PubMed ID: 31610148
[TBL] [Abstract][Full Text] [Related]
20. Potential new clinical therapies for Chagas disease.
Bustamante JM; Tarleton RL
Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
